Measuring symptoms in localized prostate cancer: A systematic review of assessment instruments

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 2, 2013, Pages 111-122

  Rnic, K ^a   Linden, W ^a,b   Tudor, I ^a   Pullmer, R ^a   Vodermaier, A ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

measures; psychometrics; reliability; symptoms; validity

Indexed keywords

CANCER LOCALIZATION; CLINICAL ASSESSMENT TOOL; CONCURRENT VALIDITY; CONSTRUCT VALIDITY; CRITERION RELATED VALIDITY; CRONBACH ALPHA COEFFICIENT; EXPANDED PROSTATE CANCER INDEX COMPOSITE 26; HUMAN; INTERNAL CONSISTENCY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER QUALITY OF LIFE; PSYCHOMETRY; RATING SCALE; REVIEW; SYSTEMATIC REVIEW; TEST RETEST RELIABILITY; UCLA PROSTATE CANCER INDEX; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE; VALIDATION STUDY;

HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; PSYCHOMETRICS; QUALITY OF LIFE; SELF REPORT;

EID: 84882450329     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.1     Document Type: Review

References (55)

1. Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW et al. Prostate Cancer Trends 1973-1995, SEER Program. National Cancer Institute NIH Pub. No. 99- 4543)Bethesda, MD, 1999.
2. Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998; 16: 275-283. (Pubitemid 28041609)
3. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20: 557-566. (Pubitemid 34072540)
4. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-135.
5. De Sousa A, Sonavane S, Mehta J. Psychological aspects of prostate cancer: a clinical review. Prostate Cancer Prostatic Dis 2012; 15: 120-127.
6. Sommers SD, Ramsey SD. A review of quality-of-life evaluations in prostate cancer. Pharmacoeconomics 1999; 16: 127-140. (Pubitemid 29450601)
7. Sonn GA, Sadetsky N, Presti JC, Litwin M. Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol 2009; 182: 2296-2302.
8. Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. J Acquir Immune Defic Syndr 1999; 21: 126-133. (Pubitemid 29250076)
9. Vodermaier A, Linden W, Siu C. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J Natl Cancer Inst 2009; 101: 1464-1488.
10. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 2002; 11: 307-326. (Pubitemid 34987589)
11. Morris C, Gibbons E, Fitzpatrick R. A structured review of patient-reported outcome measures for men with prostate cancer. Technical Report, 2009, Patient-reported Outcome Measurement Group, Department of Public Health, University of Oxford.
12. Mallet S, Deeks JJ, Halligan S, Hopewell S, Cornelius V, Altman DG. Systematic reviews of diagnostic tests in cancer: review of methods and reporting. BMJ 2006; 333: 413.
13. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to their Development and Use. Oxford University Press: New York, USA, 2008.
14. Clark JA, James A. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care 2001; 39: 1118-1130. (Pubitemid 33691385)
15. Dale W, Campbell T, Ignacio L, Song P, Kopnick M, Mamo C et al. Self-assessed health-related quality of life in men being treated for prostate cancer with radiotherapy: instrument validation and its relation to patient-assessed bother of symptoms. Int J Cancer 2000; 90: 163-172. (Pubitemid 30441518)
16. van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008; 44: 2418-2424.
17. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899-905.
18. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of the Expanded Prostate Cancer Index Composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010; 76: 1245-1250.
19. Hedgepath RC, Labo J, Zhang L, Wood DP. Expanded Prostate Cancer Index Composite versus Incontinence Symptom Index and Sexual Health Inventory for men to measure functional outcomes after prostatectomy. Urology 2009; 182: 221-228.
20. Chang P, Szymanski KM, Dunn RL, Chipman KK, Litwin MS, Nguyen PL et al. Expanded Prostate Cancer Index Composite for Clinical Practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 2011; 186: 865-872.
21. Morales Lopez A, Grau Fibla G, Campoy MP, Benavente RA, Pascual del Pobil Moreno JL. Validation of ESCAP-CD as an instrument of measure for the evaluation of the quality of life in prostatic cancer. Actas Urol Esp 2002; 26: 320-334.
22. Katz G, Rodriguez R. Use of a modified American Urological Association Symptom Score for the evaluation of the quality of life of patients with prostate cancer. Urology 2001; 57: 112-116. (Pubitemid 32065830)
23. Esper PE, Mo FE, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapyprostate instrument. Urology 1997; 50: 920-928. (Pubitemid 28021111)
24. Yount S, Cella D, Banik D, Ashraf T, Shevrin D. Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI). Health Qual Life Outcomes 2003; 1: 69.
25. Bestmann B, Rohde V, Siebmann JU, Galalae R, Weidner W, Kuchler T. Validation of the German prostate-specific module. World J Urol 2006; 24: 94-100. (Pubitemid 43298690)
26. Hosseini M, Ebrahimi SM, Alinaghi SAS, Mahmoodi M. Sensitivity and specificity of International Prostate Symptom Score (IPSS) for the screening of Iranian patients with prostate cancer. Acta Med Iran 2010; 49: 451-455.
27. Farnell DJJ, Mandall P, Anandadas C, Routledge J, Burns MP, Logue JP et al. Development of a patient-reported questionnaire for collecting toxicity data following prostate brachytherapy. Radiother Oncol 2010; 97: 136-142.
28. Robinson JP, Avi-Itzhak T, McCorkle R. Psychometric properties of the Male Urogenital Distress Inventory (MUDI) and Male Urinary Symptom Impact Questionnaire (MUSIQ) in patients following radical prostatectomy. Urol Nurs 2007; 27: 512-520.
29. Victorson DE, Beaumont JL, Rosenbloom SK, Shevrin D, Cella D. Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P symptom index. Psychooncology 2011; 2: 977-983.
30. Krahn M, Ritvo P, Irvine J, Tomlinson G, Bezjak A, Trachtenberg J et al. Construction of the Patient-Oriented Prostate Utility Scale (PORPUS): a multiattribute health state classification system for prostate cancer. J Clin Epidemiol 2000; 53: 920-930.
31. Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qual Life Res 2007; 16: 509-522. (Pubitemid 46363692)
32. Ritvo P, Irvine J, Naglie G, Tomlinson G, Bezjak A, Matthew A. Reliability and validity of the PORPUS, a combined psychometric and utility-based quality-of-life instrument for prostate cancer. J Clin Epidemiol 2005; 58: 466-474. (Pubitemid 40544568)
33. Giesler R, Miles B, Cowen M, Kattan M. Assessing quality of life in men with clinically localized prostate cancer: development of a new instrument for use in multiple settings. Qual Life Res 2000; 9: 645-665. (Pubitemid 32146993)
34. Befort CA, Zelefsky MJ, Scardino PT, Borrayo E, Giesler RB, Kattan MW. A measure of health-related quality of life among patients with localized prostate cancer: results from ongoing scale development. Clin Prostate Cancer 2005; 4: 100-108. (Pubitemid 41474604)
35. Stockler MR, Osoba D, Goodwin P, Corey P, Tannock IF. Responsiveness to change in health-related quality of life in a randomized clinical trial: a comparison of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) with analogous scales from the EORTC QLQ-C30 and a trial specific module. J Clin Epidemiol 1998; 51: 137-145. (Pubitemid 28066140)
36. Stockler MR, Osaba D, Corey P, Goodwin PJ, Tannock IF. Convergent discriminative, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a Trial-Specific Module. J Clin Epidemiol 1999; 52: 653-666. (Pubitemid 29281661)
37. Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: prostate carcinoma patients perspectives after prostatectomy or radiation therapy. Cancer 1997; 79: 1977-1986. (Pubitemid 27200383)
38. Lev EL, Eller LS, Gejerman G, Lane P, Owen SV, White M et al. Quality of life of men treated with brachytherapies for prostate cancer. Health Qual Life Outcomes 2004; 2: 28.
39. Fowler FJ, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National medicare experience: 1998-1990. Urology 1993; 42: 622-629. (Pubitemid 24004781)
40. Fossa SD. Quality of life after palliative radiotherapy in patients with hormoneresistant prostate cancer: single institution experience. Br J Urol 1994; 74: 345-351. (Pubitemid 24276094)
41. Fransson P, Tavelin B, Widmark A. Reliability and responsiveness of a prostate cancer questionnaire for radiotherapy-induced side effects. Support Care Cancer 2001; 9: 187-198. (Pubitemid 32435810)
42. Reidunsdatter RK, Lund JA, Fransson P, Widmark A, Fossa SD, Kaasa S. Validation of the intestinal part of the prostate cancer questionnaire QUFW94: psychometric properties, responsiveness, and content validity. Int J Radiat Oncol Biol Phys 2010; 77: 793-804.
43. Widmark A, Fransson P, Tavelin B. Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994; 9: 2520-2532. (Pubitemid 24320858)
44. Helgason AR, Adolfsson J, Hickman P, Fredrikson M, Arver S, Steineck G. Waning sexual function-the most important disease-specific distress for patients with prostate cancer. Br J Cancer 1996; 73: 1417-1421. (Pubitemid 26175677)
45. Al-Abany M, Helgason AR, Adolfsson J, Steineck G. Reliability of assessment of urgency and other symptoms indicating anal sphincter, large bowel or urinary dysfunction. Scand J Urol Nephrol 2006; 40: 397-408. (Pubitemid 44627526)
46. Vickers AJ, Savaje CJ, Shouery M, Eastham JA, Scardino PT, Basch EM. Validation study of a web-based assessment of functional recovery after radical prostatectomy. Health Qual Life Outcomes 2010; 8: 82.
47. Litwin MS, Hays RD, Fink A, Ganz P, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36: 1002-1012. (Pubitemid 128456439)
48. Karakiewicz PI, Kattan MW, Tanguay S, Elhilali MM, Bazinet M, Scardino PT et al. Cross-cultural validation of the UCLA Prostate Cancer Index. Urology 2003; 61: 302-307. (Pubitemid 36206521)
49. Wang H, Huang E, Dale W, Campbell T, Ignacio L, Kopnick M et al. Self-assessed health-related quality of life in men who have completed radiotherapy for prostate cancer: instrument validation and its relation to patient-assessed bother of symptoms. Intl J Cancer 2000; 90: 163-172. (Pubitemid 30441518)
50. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376. (Pubitemid 23073154)
51. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579. (Pubitemid 23071057)
52. Da Calais Silva F. Quality of life in prostatic cancer patients. Cancer 1993; 72: 3803-3806.
53. Borghede G, Sullivan M. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancerspecific module supplementing the EORTC QLQ-C30. Qual Life Res 1996; 5: 212-222. (Pubitemid 26180669)
54. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 359: 1250-1261. (Pubitemid 351439226)
55. Waldmann A, Rohde V, Bremner K, Krahn M, Kuechler T, Katalinic A. Measuring prostate-specific quality of life in prostate cancer patients scheduled for radiotherapy or radical prostatectomy and reference men in Germany and Canada using the Patient Oriented Prostate Utility Scale-Psychometric (PORPUS-P). BMC Cancer 2009; 9: 295.